Document 3157
 DOCN  M94A3157
 TI    Why isn't increased survival enough?
 DT    9412
 AU    Wilson AD; Wellcome Foundation Ltd, Beckenham, Kent.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):14 (abstract no. 030D). Unique
       Identifier : AIDSLINE ICA10/94369418
 AB    This presentation will review the four main reasons for applying
       economic analyses to the field of HIV and AIDS healthcare. These are: 1.
       Current projections of the growing number of people who may be affected
       by HIV/AIDS worldwide. 2. The predicted large degree of dependence on
       healthcare systems of people with HIV/AIDS who will require prolonged
       treatment, nursing and terminal care. 3. The impact on healthcare
       budgets of providing care to people with HIV/AIDS. 4. The current focus,
       by many industrialised countries, on containing the costs of healthcare.
       The presentation will examine the meaning of cost effectiveness in a
       healthcare setting. Cost-effectiveness is one of a family of methods for
       assessing costs and benefits in terms of efficacy or value for money.
       Currently, cost-effectiveness data exists only for Zidovudine (Retrovir,
       AZT) monotherapy and the focus of this presentation will be a review of
       the existing literature. Recently completed work including the results
       of the economic evaluation from the Cost-Effectiveness of AIDS Therapy
       (CEAT) Study is discussed. The potential of these studies to contribute
       to the information available for decision-makers is assessed. Also,
       using gap analysis, we will identify the future direction of economic
       evaluation work required, with consideration for different therapeutic
       options such as combination therapy.
 DE    *Cost of Illness  Cost-Benefit Analysis  Drug Costs  Health
       Services/*ECONOMICS/SUPPLY & DISTRIBUTION/UTILIZATION  Human  HIV
       Infections/DRUG THERAPY/*ECONOMICS  Zidovudine/THERAPEUTIC USE  MEETING
       ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).